Fig. 1 · Structure

Documents & Downloads

OSI-420

Cat. No. A10678 CAS 183320-51-6

EGFR Inhibitor

OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .

In Stock

Publications for OSI-420

2 publications citing this product

  1. Yuta Yamamoto, .et al. , J Pharm Anal, 2018, Apr; 8(2): 119-123 PMID: 29736298
  2. Janet L. Martin, .et al. , Breast Cancer Res, 2017, 19: 90 PMID: 28778177

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
EGFR 2 nM

OSI-420 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of OSI-420 from 2 published references. In vitro models include U87 human glioblastoma cells in a 47-kinase-inhibitor screen.

OSI-420 In Vitro Studies

In transporter-expressing cells, OSI-420 accumulation was reduced by BCRP and P-gp, with increased accumulation after elacridar treatment. MRP4 expression did not significantly change accumulation under the tested conditions. [1]

In a U87 glioblastoma cell screen, OSI-420 at 1 μM for 24 h did not significantly change average neurite-like process length per cell versus DMSO. This negative result is specific to the morphology endpoint and tested conditions. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Transporter-dependent OSI-420 accumulation

Cell-based study · Saos2 cells expressing BCRP or MRP4 with empty-vector controls; LLC-PK1 cells expressing human MDR1 with parental controls [1]

OSI-420 accumulation was reduced by BCRP and P-gp expression and increased by elacridar in these transfected cells. MRP4 expression produced no significant difference. These are cellular disposition endpoints, not EGFR potency or tumor-growth effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cellular OSI-420 accumulation relative to controlsDirectional accumulation comparison Reduced with BCRP and P-gp; no significant MRP4 difference; elacridar increased accumulation in BCRP and P-gp cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 μg/mL OSI-420
Exposure duration
Accumulation time course to 30 min; Figure 4B combines 15 and 30 min data
Method
Incubation at 37 °C; LC-MS/MS of cell lysates, normalized to protein
Co-treatment
Elacridar 4 μM comparator; 30 min pre-incubation
Reported limits
OSI-420 solvent and explicit biological-versus-technical identity of n=4–6 are not stated in these locations.
Methods and source locations

Compound reported in the paper: OSI-420 (O-desmethyl erlotinib); Compound label in the paper: Directly applied OSI-420 standard

Evidence concerns the reported OSI-420 material or metabolite. Hydrochloride-form equivalence and current Adooq lot performance were not tested.

Methods: Chemicals and reagents, Cell lines, Intracellular drug accumulation; Results: Intracellular accumulation experiments; Figure 4

Cellular OSI-420 accumulation relative to controls: LC-MS/MS; Figure 4: mean ± SD, n=4–6; percentages of maximum control accumulation. No exact graph percentages extracted. — Figure 4A–B and caption; Results: Intracellular accumulation experiments

No significant neurite-like process response in U87 cells

Cell-based study · U87 human glioblastoma cells in a 47-kinase-inhibitor screen [2]

OSI-420 did not significantly change average neurite-like process length per cell relative to DMSO under the screening conditions. This endpoint does not establish lack of EGFR inhibition or lack of antiproliferative activity. Later mechanistic and animal findings for CP-673451 do not apply to OSI-420.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Average neurite-like process length normalized by cell number versus DMSOStatistical screen outcome NS; p ≥ 0.05 (screen legend definition)[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
24 h
Method
Kinase inhibitor screen in 10% FBS; phase-contrast microscopy and Fiji Simple Neurite Tracer
Vehicle
DMSO
Reported limits
DMSO percentage and OSI-420-specific exact p value/effect size are not given in the checked table/caption.
Methods and source locations

Compound reported in the paper: OSI-420 (O-desmethyl erlotinib); Compound label in the paper: OSI-420 library reagent

Evidence concerns the reported OSI-420 material or metabolite. Hydrochloride-form equivalence and current Adooq lot performance were not tested.

Results: Kinase inhibitor screening; Table 1 OSI-420 row; Figure 1; Methods: Cell culture, Kinase inhibitor treatment/screening, Light microscopy and neurite-like process length analysis, Statistical analysis

Average neurite-like process length normalized by cell number versus DMSO: Table 1; Figure 1: mean ± SD of n=3 independent experiments; two-tailed t-test. Methods describe three technical repeats and nine images per well. — Table 1 OSI-420 row; Figure 1 caption; Methods: microscopy and statistics

OSI-420 In Vivo Studies

Following a single oral erlotinib dose in mice, the OSI-420 metabolite had a brain extracellular-fluid-to-unbound plasma AUC ratio of 0.07 ± 0.02 in wild-type animals. Ratios increased in Abcg2-deficient and combined Mdr1a/b/Abcg2-deficient mice, but not in Mdr1a/b- or Abcc4-deficient mice. These results describe metabolite distribution after erlotinib administration, not direct OSI-420 treatment. [1]

Brain extracellular-fluid distribution of the erlotinib metabolite

Animal study · Female FVB-background mice, 3–4 months old: wild-type, Abcg2−/−, Mdr1a/b−/−, Mdr1a/b−/−Abcg2−/− and Abcc4−/− [1]

After erlotinib dosing, OSI-420 brain ECF-to-unbound plasma AUC ratios were higher in Abcg2-deficient and double-knockout mice, but were not increased in the Mdr1a/b- or Abcc4-deficient groups. This measures a metabolite formed in vivo; it does not establish OSI-420 hydrochloride dosing, efficacy or human CNS penetration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Brain ECF AUC0–24 divided by unbound plasma AUC0–24 for OSI-420PBrain (dimensionless; mean ± SD) Wild-type 0.07 ± 0.02; Abcg2−/− 0.51 ± 0.04; Mdr1a/b−/− 0.04 ± 0.02; double knockout 0.34 ± 0.21; Abcc4−/− 0.08 ± 0.06[1]

Conditions shared by the study groups

Route
Oral gavage of erlotinib
Frequency
Single dose
Treatment course
Brain ECF and plasma exposure assessed over 0–24 h
Vehicle
0.2% carboxymethylcellulose and 0.05% Tween 20
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type
Erlotinib 50 mg/kg; OSI-420 measured as a formed metabolite, not administered
Reference strain for knockout comparisons.OSI-420 PBrain: 0.07 ± 0.02 (mean ± SD).[1]
Abcg2 knockout
Erlotinib 50 mg/kg; OSI-420 measured as a formed metabolite, not administered
Wild-type mice receiving the same erlotinib regimen.OSI-420 PBrain: 0.51 ± 0.04 (mean ± SD); significantly higher than wild-type.[1]
Mdr1a/b knockout
Erlotinib 50 mg/kg; OSI-420 measured as a formed metabolite, not administered
Wild-type mice receiving the same erlotinib regimen.OSI-420 PBrain: 0.04 ± 0.02 (mean ± SD); not enhanced versus wild-type (p > 0.05).[1]
Combined Mdr1a/b and Abcg2 knockout
Erlotinib 50 mg/kg; OSI-420 measured as a formed metabolite, not administered
Wild-type mice receiving the same erlotinib regimen.OSI-420 PBrain: 0.34 ± 0.21 (mean ± SD); higher than wild-type (p < 0.01).[1]
Abcc4 knockout
Erlotinib 50 mg/kg; OSI-420 measured as a formed metabolite, not administered
Wild-type mice receiving the same erlotinib regimen.OSI-420 PBrain: 0.08 ± 0.06 (mean ± SD); similar to wild-type (p > 0.05).[1]
Wild-type
Model: Wild-type FVB-background female mice, 3–4 months old
Reported limits: Figure 3 specifies 4–7 mice per group; individual wild-type n is not specified in the result paragraph.
Abcg2 knockout
Model: Abcg2−/− FVB-background female mice, 3–4 months old; n=5
Reported limits: Text gives p < 0.05; Figure 3 uses a double-asterisk marker. Only significance, not a single exact threshold, is asserted here.
Mdr1a/b knockout
Model: Mdr1a/b−/− FVB-background female mice, 3–4 months old; n=4
Combined Mdr1a/b and Abcg2 knockout
Model: Mdr1a/b−/−Abcg2−/− FVB-background female mice, 3–4 months old; n=5
Abcc4 knockout
Model: Abcc4−/− FVB-background female mice, 3–4 months old; n=4
Methods and source locations

Compound reported in the paper: OSI-420 (O-desmethyl erlotinib); Compound label in the paper: Measured OSI-420 metabolite after erlotinib dosing

Evidence concerns the reported OSI-420 material or metabolite. Hydrochloride-form equivalence and current Adooq lot performance were not tested.

Methods: Animals, protein binding, plasma PK/model, microdialysis/recovery and PK analysis; Results: Increased ECF penetration; Figure 3

Brain ECF AUC0–24 divided by unbound plasma AUC0–24 for OSI-420: Microdialysis with zero-flow recovery correction, LC-MS/MS and PK modeling; 4–7 mice/group (Figure 3); knockout comparisons by Mann–Whitney test. — Results: Increased ECF penetration; Figure 3A and caption

Wild-type · Methods: Animals, Erlotinib brain microdialysis studies, Pharmacokinetic analysis; Results: Increased ECF penetration; Figure 3A

Abcg2 knockout · Methods: Animals, Erlotinib brain microdialysis studies, Pharmacokinetic analysis; Results: Increased ECF penetration; Figure 3A

Mdr1a/b knockout · Methods: Animals, Erlotinib brain microdialysis studies, Pharmacokinetic analysis; Results: Increased ECF penetration; Figure 3A

Combined Mdr1a/b and Abcg2 knockout · Methods: Animals, Erlotinib brain microdialysis studies, Pharmacokinetic analysis; Results: Increased ECF penetration; Figure 3A

Abcc4 knockout · Methods: Animals, Erlotinib brain microdialysis studies, Pharmacokinetic analysis; Results: Increased ECF penetration; Figure 3A

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 183320-51-6
Applications EGFR Inhibitor
Formula C21H21N3O4.HCl
Molecular Weight 415.9
Synonyms Desmethyl Erlotinib; CP-473420
SMILES
COCCOC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCO.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 75 mg/mL (180.34 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

OSI-420 Research References

  1. [1] Elmeliegy MA, Carcaboso AM, Tagen M, et al. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21088257 DOI: 10.1158/1078-0432.ccr-10-1934 Source material
  2. [2] Lane R, Cilibrasi C, Chen J, et al. PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling. Oncogene (2022). PMID: 35393545 DOI: 10.1038/s41388-022-02294-x Source material

Publications

2 publications citing this product

  1. Yuta Yamamoto, .et al. , J Pharm Anal, 2018, Apr; 8(2): 119-123 PMID: 29736298
  2. Janet L. Martin, .et al. , Breast Cancer Res, 2017, 19: 90 PMID: 28778177

Added to your cart

View Cart Checkout
Loading...